SCHEMBL1810048

SCHEMBL1810048

Cn1c(=O)c2c(ncn2CCN2CCN(c3ccccc3)CC2)n(C)c1=O

nearest known ligand 0.84

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.84
HTR6 P50406 1/20 0.84
L3MBTL1 Q9Y468 1/20 0.70
ALDH1A1 P00352 2/20 0.61
HTR1A P08908 2/20 0.60
HTR2A P28223 2/20 0.60
ADORA2B P29275 4/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
TSHR P16473 1/20 0.59
HTT P42858 1/20 0.58
RAB9A P51151 1/20 0.56
MAPK1 P28482 1/20 0.56
MAPT P10636 1/20 0.54
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683655 0.91 HTR7 (0.77) HTR7HTR6L3MBTL1ALDH1A1HTR1A
SCHEMBL14299185 0.90 HTR7 (0.69) HTR7HTR6L3MBTL1ALDH1A1HTR1A
SCHEMBL10896437 0.89 HTR7 (0.85) HTR7HTR6L3MBTL1ALDH1A1HTR1A
SCHEMBL4478721 0.89 HTR6 (0.67) HTR7HTR6L3MBTL1HTR1AADORA2B
SCHEMBL4462834 0.88 MAPK1 (0.72) HTR7HTR6L3MBTL1ALDH1A1HTR1A
SCHEMBL11148728 0.87 RXFP1 (0.65) HTR7HTR6L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL12578899 0.87 HTR7 (0.65) HTR7HTR6L3MBTL1ALDH1A1HTR1A
SCHEMBL4468785 0.86 HTR7 (0.64) HTR7HTR6L3MBTL1ALDH1A1HTR1A
SCHEMBL4461767 0.86 ADORA2B (0.73) HTR7HTR6L3MBTL1ALDH1A1ADORA2B
SCHEMBL14299540 0.86 HTR7 (0.64) HTR7HTR6L3MBTL1ALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118464-A1 HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF KAOHSIUNG MEDICAL UNIVERSITY 2011-05-19 US disclosed
US-20110118464-A1 HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF KAOHSIUNG MEDICAL UNIVERSITY 2011-05-19 US disclosed
US-20110118464-A1 HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF KAOHSIUNG MEDICAL UNIVERSITY 2011-05-19 US disclosed
US-7550468-B2 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2009-06-23 US disclosed
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118464-A1 HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF TK1, XDH, KYAT1 HTR7 2141/4885HTR6 3272/4885L3MBTL1 197/4885
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase PDE3A, PDE5A, PDE3B HTR7 120/4885HTR6 510/4885L3MBTL1 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.